News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Valeant (VRX)'s Many Acquisitions Led to Manufacturing Issues, Says the FDA



11/9/2016 7:14:00 AM

  Life Sciences Jobs  
  • Newest Jobs - Last 24 Hours
  • California Jobs
  • Massachusetts Jobs
  • New Jersey Jobs
  • Maryland Jobs
  • Washington Jobs
  View More Jobs
As if Joe Papa doesn’t have enough problems.

The Valeant Pharmaceuticals chief executive is grappling with numerous government probes into the company’s accounting and pricing practices; its business strategy is in turmoil; assets are being sold to ward off bondholders and its stock is tanking, again.

Now, the US Food and Drug Administration has sent a warning letter that notes the company is having manufacturing problems that reflect an inability to integrate some of the products that have been scooped up as a result of its many acquisitions.

Read at STAT


comments powered by Disqus
STAT
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES